Your browser doesn't support javascript.
loading
Phase I clinical trial of a five-peptide cancer vaccine combined with cyclophosphamide in advanced solid tumors.
Murahashi, Mutsunori; Hijikata, Yasuki; Yamada, Kazunari; Tanaka, Yoshihiro; Kishimoto, Junji; Inoue, Hiroyuki; Marumoto, Tomotoshi; Takahashi, Atsushi; Okazaki, Toshihiko; Takeda, Kazuyoshi; Hirakawa, Masakazu; Fujii, Hiroshi; Okano, Shinji; Morita, Masaru; Baba, Eishi; Mizumoto, Kazuhiro; Maehara, Yoshihiko; Tanaka, Masao; Akashi, Koichi; Nakanishi, Yoichi; Yoshida, Koji; Tsunoda, Takuya; Tamura, Kazuo; Nakamura, Yusuke; Tani, Kenzaburo.
Afiliación
  • Murahashi M; Department of Advanced Cell and Molecular Therapy, Kyushu University Hospital, Fukuoka, Japan.
  • Hijikata Y; Department of Advanced Cell and Molecular Therapy, Kyushu University Hospital, Fukuoka, Japan.
  • Yamada K; Department of Advanced Cell and Molecular Therapy, Kyushu University Hospital, Fukuoka, Japan.
  • Tanaka Y; Division of Molecular and Clinical Genetics, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan.
  • Kishimoto J; Digital Medicine Initiative, Kyushu University, Fukuoka, Japan.
  • Inoue H; Division of Molecular and Clinical Genetics, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan.
  • Marumoto T; Division of Molecular and Clinical Genetics, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan.
  • Takahashi A; Division of Molecular and Clinical Genetics, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan.
  • Okazaki T; Department of Advanced Cell and Molecular Therapy, Kyushu University Hospital, Fukuoka, Japan.
  • Takeda K; Department of Immunology, Juntendo University School of Medicine, Tokyo, Japan.
  • Hirakawa M; Department of Radiology, Kyushu University Hospital, Fukuoka, Japan.
  • Fujii H; Department of Pathology, Kyushu University, Fukuoka, Japan.
  • Okano S; Department of Pathology, Kyushu University, Fukuoka, Japan.
  • Morita M; Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Baba E; Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.
  • Mizumoto K; Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Maehara Y; Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Tanaka M; Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Akashi K; Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.
  • Nakanishi Y; Institute of Diseases of Chest, Kyushu University, Fukuoka, Japan.
  • Yoshida K; Human Genome Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
  • Tsunoda T; Human Genome Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
  • Tamura K; Division of Oncology, Hematology and Infectious Diseases, Department of Internal Medicine, Fukuoka University, Fukuoka, Japan.
  • Nakamura Y; Human Genome Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
  • Tani K; Department of Advanced Cell and Molecular Therapy, Kyushu University Hospital, Fukuoka, Japan; Division of Molecular and Clinical Genetics, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan. Electronic address: k-tani@ims.u-tokyo.ac.jp.
Clin Immunol ; 166-167: 48-58, 2016 05.
Article en En | MEDLINE | ID: mdl-27072896
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico; Vacunas contra el Cáncer/inmunología; Ciclofosfamida/inmunología; Neoplasias/tratamiento farmacológico; Neoplasias/inmunología; Vacunas de Subunidad/inmunología; Adulto; Anciano; Anciano de 80 o más Años; Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos; Protocolos de Quimioterapia Combinada Antineoplásica/inmunología; Vacunas contra el Cáncer/administración & dosificación; Vacunas contra el Cáncer/efectos adversos; Neoplasias Colorrectales/tratamiento farmacológico; Neoplasias Colorrectales/genética; Neoplasias Colorrectales/inmunología; Ciclofosfamida/administración & dosificación; Ciclofosfamida/efectos adversos; Relación Dosis-Respuesta a Droga; Esquema de Medicación; Epítopos/administración & dosificación; Epítopos/inmunología; Femenino; Antígeno HLA-A24/genética; Antígeno HLA-A24/inmunología; Humanos; Estimación de Kaplan-Meier; Leucopenia/inducido químicamente; Neoplasias Pulmonares/tratamiento farmacológico; Neoplasias Pulmonares/genética; Neoplasias Pulmonares/inmunología; Masculino; Persona de Mediana Edad; Neoplasias/genética; Péptidos/administración & dosificación; Péptidos/inmunología; Neoplasias Gástricas/tratamiento farmacológico; Neoplasias Gástricas/genética; Neoplasias Gástricas/inmunología; Linfocitos T/efectos de los fármacos; Linfocitos T/inmunología; Linfocitos T/metabolismo; Resultado del Tratamiento; Vacunas de Subunidad/administración & dosificación; Vacunas de Subunidad/efectos adversos
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Vacunas contra el Cáncer / Vacunas de Subunidad / Ciclofosfamida / Neoplasias Límite: Aged80 Idioma: En Revista: Clin Immunol Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2016 Tipo del documento: Article País de afiliación: Japón
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Vacunas contra el Cáncer / Vacunas de Subunidad / Ciclofosfamida / Neoplasias Límite: Aged80 Idioma: En Revista: Clin Immunol Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2016 Tipo del documento: Article País de afiliación: Japón